Oxford College of London

Study Graduate and Postgraduate courses at Highly Trusted College.

Harvard University

Harvard University, which celebrated its 375th anniversary in 2011

Washington University in St. Louis

Washington University in St. Louis (Washington University, Wash. U., or WUSTL) is a private research university located in suburban St. Louis, Missouri, United States. Founded in 1853, and named for George Washington

Edith Cowan University Western Australia

Edith Cowan is a multi-campus institution, offering undergraduate and postgraduate courses in Perth and Bunbury, Western Australia.

Showing posts with label mutation. Show all posts
Showing posts with label mutation. Show all posts

Thursday, November 29, 2012

Architecture of rod sensory cilium disrupted by mutation

Graciela Gutierrez713-798-4710

HOUSTON -- (November 21, 2012) -- Using a new technique called cryo-electron tomography, two research teams at Baylor College of Medicine have created a three-dimensional map that gives a better understanding of how the architecture of the rod sensory cilium (part of one type of photoreceptor in the eye) is changed by genetic mutation and how that affects its ability to transport proteins as part of the light-sensing process.

Almost all mammalian cells have cilia. Some are motile and some are not. They play a central role in cellular operations, and when they are defective because of genetic mutations, people can go blind, have cognitive defects, develop kidney disease, grow too many fingers or toes or become obese. Such mutations cause cilia defects known in the aggregate as ciliopathies.

"The major significance of this report lies in our being able to, for the first time, look in three dimensions at the structural alterations in ciliopathies," said Dr. Theodore G. Wensel, chair of biochemistry and molecular biology at BCM and corresponding author of the report that appears in the journal Cell. The report is spotlighted on the issue’s cover.

In collaboration with the National Center for Macromolecular Imaging, led by Dr. Wah Chiu, professor of biochemistry and molecular biology at BCM, Wensel and his colleagues established such three dimensional images for cilia in three examples of mice known to have cilopathies.

These mice have genetic mutations that lead to defects in the structure of the rod outer segment. The rod outer segment is part of the photoreceptor in the retina called a rod. The rod outer segment contains photosensitive disk membranes that carry rhodopsin, the biological pigment in photoreceptor cells of the retina responsible for the first events that result in the perception of light.

Using cryo-electron tomography, the scientists compared the structures of the rod outer segment in the mutant mice to those in normal mice.

"This is one of the few places in the world where you could do this," said Wensel. The center, run by Chiu, has powerful cryo-electron microscopes that make tomography possible. To achieve the
three-dimensional reconstruction, Dr. Juan T. Chang in Chiu’s center froze the photoreceptors purified by then-graduate student Jared Gilliam in a special way that made it possible to perform electron microscopy. During the microscopy session, the frozen samples were carefully tilted allowing the researchers to take many two-dimensional images that were used in the computer reconstruction of the three-dimensional map.

The light-sensing outer segments of photoreceptors in the retina are connected to the machinery responsible for protein production in the inner segment by a thin cylindrical bundle of microtubules known as the connecting cilium.

"There is a huge flux of material from the inner segment to the outer segment of the photoreceptor," said Wensel. "When there is a defect, then the animal or patient goes blind."

The three-dimensional structure showed that there are vesicles (small sacs) tethered to membrane filaments.

"It looks as though these vesicles that are tethered contain material that will fuse to the plasma membrane and go up the membrane to the outer segment," said Wensel.

In studies of a mouse model of a disease called Bardet Biedl syndrome, developed by the laboratory of Dr. James Lupski, professor of molecular and human genetics at BCM, Wensel and first author Gilliam saw something that was almost shocking--a huge accumulation of these vesicles. The Bardet Biedl genes contain the code for a BBsome that forms a membrane coat that makes transport possible through the connecting cilium to the outer coat.

"We would now surmise that the BBsome coat is required for fusion of the plasma membrane or transport up to the outer segment," said Wensel. "It gives us a whole new model for how this works. We need to do more now to nail it down."

"It suggests that aberrant trafficking of proteins is responsible for photoreceptor degeneration," said Gilliam, who is now a postdoctoral associate at The University of Texas Health Science Center at Houston.

Others who took part in the research include: BCM graduate student Ivette Sandoval; Youwen Zhang and Steven J. Pittler, both of the University of Alabama at Birmingham; and Tiansen Li of the National Eye Institute in Bethesda, Maryland. Wensel is the Robert A. Welch Chair in Chemistry, Chiu is the Alvin Romansky Chair in Biochemistry and Lupski is the Cullen Foundation Endowed Chair in Molecular Genetics.

Funding for this work came from the National Institutes of Health (EY011900 and EY07981, 41RR002250, EY018143, EY10309, EY10581, EY011731, T32EY007001, Vision Research Core Grant EY002520) and the Robert Welch Foundation.


View the original article here

Muscle weakness in mice with mutation for MD1 reduced

Graciela Gutierrez713-798-4710

HOUSTON -- (November 20, 2012) -- Muscle weakness, muscle wasting and myotonia are the most common symptoms of myotonic dystrophy type 1, but the question remains, what are the underlying mechanisms that affect this disorder. Researchers from Baylor College of Medicine are now closer to finding an answer after identifying an enzyme that when inhibited can reduce muscle weakness and myotonia in mice with the mutation for myotonic dystrophy type 1.

The findings, which appear in the current edition of The Journal of Clinical Investigation, open the door for future research into developing more effective treatment options.

Developing treatment options

"We have known that this disorder is caused by a genetic mutation that leads to accumulation of RNA repeats interfering with the function of RNA-binding proteins," said Dr. Lubov T. Timchenko, professor of molecular physiology and biophysics at BCM and lead author on the study. "What we found in this study is that these mutant repeats cause a chain reaction that leads to the increased activity of an enzyme known as GSK3ß."

Timchenko and her colleagues found that this enzyme was elevated in skeletal muscle biopsy samples from patients with myotonic dystrophy type 1 and from mouse models with the mutation. They reasoned that normalizing GSK3ß could be one way to target the disorder.

Using a GSK3ß inhibitor made up of lithium, a commonly used treatment for certain neurological disorders, researchers found that there was a reduction in muscle weakness and myotonia. They also found that if GSK3ß was inhibited in mice with the genetic mutation before symptoms began, then there was a delay in the development of muscle weakness.

Reducing muscle weakness

"This is important because myotonic dystrophy type 1 is a progressive disease. More studies are needed but these results show us that we may one day be able to begin treatment early to delay the onset of symptoms," said Timchenko.

Patients with this disorder are known to have reduced activity in a certain type of cell called myogenic satellite cells. Timchenko said in the mouse model study, the GSK3ß inhibitors worked by activating these myogenic satellite cells, which in turn reduce muscle weakness.

Researchers also noted that even when treatment was stopped, they could still see positive results in follow up examinations of myotonia. While muscle weakness and myotonia were reduced in mice, more studies are needed to determine whether damage to muscles caused by the disease can be repaired in patients with myotonic dystrophy type 1.

Understanding the symptoms

"Myotonic dystrophy type 1 has many symptoms and affects the body in different ways. We focused on the muscle weakness and myotonia because they are the most common symptoms. Before this treatment can be used for people suffering from this disorder, we must determine what else is affected by these inhibitors," Timchenko said. "While these tests are in the lab right now, the results give us a clear pathway towards clinical studies."

This study took part in collaboration with: Karlie Jones and Christina Wei, research assistants in molecular physiology and biophysics at BCM; Polina Iakova, research associate, Huffington Center on Aging at BCM; Enrico Bugiardini and Giovanni Meola, department of neurology, University of Milan; Christiane Schneider-Gold, department of neurology, St. Josef Hospital of the Ruhr-University of Bochum, Germany; James Woodgett, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Canada; James Killian, professor of neurology at BCM; and Nikolai A. Timchenko, professor with the Huffington Center on Aging at BCM.

Funding for this study came from grants from the National Institutes of Health and the French Association on Myopathies. The authors would also acknowledged rotation student John Leach, department of physiology Ph.D. program at BCM, for the initial experiments with mouse treatments.


View the original article here